Access to bacteriophage therapy: Discouraging experiences from the human cell and tissue legal framework

FEMS Microbiology Letters

Volumn 363, Issue 4, 2016, Pages

  Verbeken, G ^a,b,c   Huys, I ^b   De Vos, D ^a,c   De Coninck, A ^d   Roseeuw, D ^d   Kets, E ^a   Vanderkelen, A ^a   Draye, J P ^a   Rose, T ^a   Jennes, S ^a   Ceulemans, C ^c   Pirnay, J P ^a  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ROYAL MILITARY ACADEMY   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Advanced therapy medicinal products; Bacteriophage therapy; Biological medicinal products; Hospital exemption; Keratinocytes; regulatory

Indexed keywords

ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; BURN; FECAL MICROBIOTA TRANSPLANTATION; GENE THERAPY; HEALTH CARE ACCESS; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; LEGAL ASPECT; MEDICAL RESEARCH; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SAFETY; SKIN INJURY; SOMATIC CELL THERAPY; TISSUE ENGINEERING; VIROTHERAPY; BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; EUROPE; GOVERNMENT REGULATION; GROWTH, DEVELOPMENT AND AGING; HISTORY; ISOLATION AND PURIFICATION; KERATINOCYTE; MICROBIOLOGY; STANDARDS;

BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; EUROPE; FECAL MICROBIOTA TRANSPLANTATION; GOVERNMENT REGULATION; HISTORY, 20TH CENTURY; HUMANS; KERATINOCYTES;

EID: 84960171994     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1093/femsle/fnv241     Document Type: Article

References (29)

1. AMR Control. Overcoming Global Antimicrobial Resistance. 2015, http://www.globalhealthdynamics.co.uk/wp-content/uploads/2015/06/AMR2015-June-3.pdf (22 December 2015, date last accessed).
2. Atiyeh BS, Costagliola M. Cultured epithelial autograft (CEA) in burn treatment: three decades later. Burns 2007;33: 405-13.
3. ATMP. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. 2007, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF (5 January 2016, date last accessed).
4. Blaser M. Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues. 1st edn. New York: Henry Holt and Company, 2014.
5. BMPL. March 25th 1964. Belgian Law on Medicinal Products (Compiled; 2014). 2014, http://www.ejustice.just.fgov.be/cgi loi/change lg.pl?language=nl&la=N&cn=1964032530&table name=wet (22 December 2015, date last accessed).
6. Bredin Prat Lawyers Office. Avis Ĥ opital Militaire Reine Astrid - Keratinocytes (in French). 2012.
7. CDCP. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013, http://www.cdc.gov/drugresistance/threat-report-2013/ (22 December 2015, date last accessed).
8. Commission Report. Report from the Commission to the European Parliament and the Council in accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. 2014, http://ec.europa.eu/transparency/regdoc/rep/1/2014/EN/1-2014-188-EN-F1-1.Pdf.
9. De Corte P, Verween G, Verbeken G et al. Feeder layer- and animal product-free culture of neonatal foreskin keratinocytes: Improved performance, usability, quality and safety. Cell Tissue Bank 2012;13:175-89.
10. De Vrieze J. The promise of poop. Science 2013;341:954-7.
11. ECDC/EMA. ECDC/EMEA Joint Technical report. The bacterial challenge: time to react. 2009, http://www.ecdc.europa.eu/en/publications/Publications/0909 TER The Bacterial Challenge Time to React.pdf (27 September 2015, date last accessed).
12. ECTD. European Cell- and Tissue Directive 2004/23/EC of the European Parliament and of the council of 31 March 2004on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. 2004, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32004L0 023:EN:HTML (5 January 2016, date last accessed).
13. EMPD. European Directive 2001/83/EC of the European parliament and of the council on the Community code relating to medicinal products for human use of 6 November 2001; 2001L0083 - EN - 16.11.2012 - 011.001 - 1 (Compiled; 2014).2014, http://www.ema.europa.eu/docs/en GB/document library/Regulatory and procedural guideline/2009/10/WC500004481.pdf (5 January 2016, date last accessed).
14. Huys I, Pirnay JP, Lavigne R et al. Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep 2013;14:951-4.
15. Helsinki. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. 64th WMA General Assembly, Fortaleza, Brazil, October 2013. 2013, http://www.wma.net/en/30publications/10policies/b3/ (22 December 2015, date last accessed).
16. Kaźmierczak Z, Górski A, Dabrowska K. Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. Viruses 2014;6:2551-70 .
17. Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 2010;11:69-86.
18. Merabishvili M, Pirnay JP, Verbeken G et al. Quality-controlled small-scale production of awell-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009;4:e4944.
19. Parracho HM, Burrowes BH, EnrightMCet al.The roleof regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genet Med 2012;6:279-86.
20. Pirnay JP, Blasdel B, Bretaudeau L et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res 2015;32:2173-9.
21. Pirnay JP, De Vos D, Verbeken G et al. The phage therapy paradigm: pr et- a-porter or sur-mesure? Pharm Res 2011;28:934-7.
22. Pirnay JP, Vanderkelen A, De Vos D et al. Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. Cell Tissue Bank 2013;14:525-60.
23. Reardon S. Phage therapy gets revitalized. Nature 2014;510:15-6.
24. Rose T, Verbeken G, De Vos D et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 2014;4:66-73.
25. Smith MB, Kelly C, Alm EJ. Policy: How to regulate fecal transplants. Nature 2014;506:290-301.
26. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15.
27. Verbeken G, Huys I, Pirnay JP et alTaking bacteriophage therapy seriously: a moral argument. Taking bacteriophage therapy seriously: a moral argument. Biomed Res Int 2014a;2014:621316.
28. Verbeken G, Pirnay JP, Lavigne R et al. Call for a dedicated European legal framework for bacteriophage therapy. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz) 2014b;62:117-29 .
29. WMA Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects.